The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Adoption of hypofractionated radiotherapy (HyRT) for ductal carcinoma in situ (DCIS): A SEER-Medicare study.
Aaron David Falchook
No relevant relationships to disclose
Laura H. Hendrix
No relevant relationships to disclose
Noam Avraham VanderWalde
No relevant relationships to disclose
Timothy M. Zagar
No relevant relationships to disclose
Ellen Jones
No relevant relationships to disclose
Reshma Jagsi
Consultant or Advisory Role - Eviti
Research Funding - AbbVie
Ronald C. Chen
No relevant relationships to disclose